

# You Can Make New Treatments Possible

## WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
<b>DUPLEX</b> (Retrophin)	FSGS	8–75	Sparsentan	≥ 30
<b>THE PODO TRIAL</b> (Pfizer)	FSGS	18+	PF-06730512	≥ 30
<b>LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC AND ADULT PATIENTS WITH FSGS</b> (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0–75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
<b>STUDY OF VX-147 IN ADULTS WITH APOL1-MEDIATED FSGS</b> (Vertex)	FSGS	18–60	VX-147	N/A
<b>STUDY OF TRPC5 CHANNEL INHIBITOR IN FSGS &amp; TREATMENT RESISTANT MINIMAL CHANGE DISEASE</b> (Goldfinch Bio)	FSGS, treatment-resistant MCD	18–75	GFB-887	≥ 45
<b>ACTION (AUSTRALIA - ACTIVE, NOT RECRUITING)</b> (Dimerix)	FSGS	18–80	Propagermanium	≥ 25
<b>EFFICACY &amp; SAFETY OF BLESELUMAB TO PREVENT RECURRENCE</b> (Astellas)	De novo transplant due to FSGS	18+	Bleselumab (added to SOC)	N/A
<b>PROTECT</b> (Retrophin)	IgAN	18+	Sparsentan	≥ 30
<b>THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING)</b> (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
<b>STUDY OF CEMDISIRAN IN ADULTS WITH IGAN</b> (Alnylam)	IgAN	18–65	Cemdisiran	UPCR ≥ 1 gram/24 hours
<b>SAFETY OF OMS721 IN IGAN, MN, C3G, DENSE DEPOSIT, AND LN PATIENTS</b> (Omeros)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	Narsoplimab	≥ 30
<b>NEFIGARD</b> (Calliditas)	IgAN	18+	Nefecon	≥ 45
<b>SAFETY AND TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGAN (CALIFORNIA, EL PASO TEXAS, AND LONDON)</b> (Aduro Biotech)	IgAN	18+	BION-1301	> 45
<b>SAFETY AND EFFICACY OF AVB-S6-500 IN ADULTS WITH IGAN (COLORADO AND FLORIDA)</b> (Aravive)	IgAN	18+	AVB-S6-500	≥ 45
<b>SAFETY AND EFFICACY OF LNP023 IN ADULTS WITH KIDNEY DISEASE CAUSED BY INFLAMMATION</b> (Novartis)	IgAN	18+	LNP023	≥ 30

Visit [KidneyHealthGateway.com](https://KidneyHealthGateway.com) to play your part in cutting-edge kidney research.



This is a living document and was last updated on 8/12/20.

See next page for more IgAN, C3G, C3GN, and MN Trials.

# You Can Make New Treatments Possible

## WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

<b>TRIAL NAME</b> (sponsor)	<b>PATIENT DIAGNOSIS</b>	<b>AGE RANGE</b>	<b>DRUG/ COMPOUND</b>	<b>EGFR IN ML/MIN</b>
<b>STUDY OF VIS649 FOR IGAN</b> (Visterra)	IgAN	18+	VIS649	≥ 45
<b>ACH-0144471 FOR C3G, C3GN, AND IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING)</b> (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≥ 75
<b>ACCOLADE</b> (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
<b>EFFICACY AND SAFETY OF LNP023 IN C3G PATIENTS TRANSPLANTED AND NOT TRANSPLANTED</b> (Novartis)	C3G or C3GN	18–65	LNP023	≥ 30
<b>EFFICACY AND SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN</b> (Novartis)	MN	18+	LNP023	≥ 45
<b>EFFICACY AND SAFETY OF MOR202 IN ANTI-PLA2R + MEMBRANOUS NEPHROPATHY (M-PLACE)</b> (MorphoSys)	MN	18-80	MOR202	≥ 50

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 8/12/20.



**NEPHCURE**<sup>®</sup>  
Kidney International